Cellectar Biosciences Statistics
Total Valuation
CLRB has a market cap or net worth of $10.82 million. The enterprise value is $233,498.
Important Dates
The next confirmed earnings date is Thursday, November 13, 2025, before market open.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLRB has 3.19 million shares outstanding. The number of shares has increased by 91.94% in one year.
| Current Share Class | 3.19M |
| Shares Outstanding | 3.19M |
| Shares Change (YoY) | +91.94% |
| Shares Change (QoQ) | +4.74% |
| Owned by Insiders (%) | 5.68% |
| Owned by Institutions (%) | 6.59% |
| Float | 3.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.10 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.15 |
| Quick Ratio | 1.88 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -273.88% and return on invested capital (ROIC) is -216.70%.
| Return on Equity (ROE) | -273.88% |
| Return on Assets (ROA) | -111.74% |
| Return on Invested Capital (ROIC) | -216.70% |
| Return on Capital Employed (ROCE) | -491.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.64M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLRB has paid $66,000 in taxes.
| Income Tax | 66,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.54% in the last 52 weeks. The beta is 0.48, so CLRB's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -94.54% |
| 50-Day Moving Average | 4.72 |
| 200-Day Moving Average | 7.02 |
| Relative Strength Index (RSI) | 33.66 |
| Average Volume (20 Days) | 313,096 |
Short Selling Information
The latest short interest is 155,620, so 4.88% of the outstanding shares have been sold short.
| Short Interest | 155,620 |
| Short Previous Month | 111,135 |
| Short % of Shares Out | 4.88% |
| Short % of Float | 5.17% |
| Short Ratio (days to cover) | 1.49 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.51M |
| Pretax Income | -29.01M |
| Net Income | -29.07M |
| EBITDA | -38.26M |
| EBIT | -38.51M |
| Earnings Per Share (EPS) | -$24.83 |
Full Income StatementBalance Sheet
The company has $11.04 million in cash and $453,509 in debt, giving a net cash position of $10.59 million or $3.32 per share.
| Cash & Cash Equivalents | 11.04M |
| Total Debt | 453,509 |
| Net Cash | 10.59M |
| Net Cash Per Share | $3.32 |
| Equity (Book Value) | 7.47M |
| Book Value Per Share | 3.07 |
| Working Capital | 6.75M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.58 million and capital expenditures -$61,286, giving a free cash flow of -$34.64 million.
| Operating Cash Flow | -34.58M |
| Capital Expenditures | -61,286 |
| Free Cash Flow | -34.64M |
| FCF Per Share | -$10.85 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
